Protocol Ledger

Biopharma Industry · Consolidated Sponsor Hub

TJ Biopharma Co: Clinical Trials & FDA Approval Profile

TJ Biopharma Co (Global / Institutional) sponsors 16 reconciled interventional Phase II and Phase III ClinicalTrials.gov studies (2018 to 2026), including 4 active protocols (2 recruiting now), 7 completed protocols, and 0 all-time original FDA Drugs@FDA NDA and BLA approvals.

Primary Focus: Oncology and Hematology Interactive Workbench: Open Full Annual Timeline & Compare ->
Track in Studio / Generate Client Brief ->
Early-Stop Rate vs National (13.8%)18.8%
Median Closed Enrollment vs National (145 pts)105 participants

Verified Sponsor Execution & Regulatory Ledger

Reconciled ClinicalTrials.gov v2 & Drugs@FDA Metrics for TJ Biopharma Co
Sponsor MetricVerified Count / Rate
Phase II & III Protocols (2018 to 2026)16
Active Pipeline (Recruiting Now)4 (2)
Completed vs Stopped Early7 / 3 (18.8%)
Median Closed Actual Enrollment105 participants
Physical Hospital Site Disclosure100.0% named hospitals
FDA Drugs@FDA Original NDA/BLA Approvals0 (0 since 2018)

Top Partner U.S. Hospital Clinical Research Sites

Canonical Hospital Campuses Partnered With TJ Biopharma Co
Hospital Research SiteLocationShared Protocols
The First Affiliated Hospital of Nanchang UniversityNanchang, Jiangxi5
The First Affiliated Hospital of Anhui Medical UniversityHefei, Anhui5
Hubei Cancer HospitalWuhan, Hubei5

Indexed Multi-Center Phase II & III Protocols

Representative ClinicalTrials.gov v2 Studies Sponsored by TJ Biopharma Co
NCT IdentifierProtocol Brief TitlePhaseStatus
NCT07208058A Phase III Clinical Study to Evaluate the Efficacy, Safety, and Tolerability of Plonmarlimab in Subjects With Relapsed/Refractory RheumaticPhase IIIRECRUITING
NCT07453004A Study to Evaluate the Efficacy,Safety,Tolerability,Pharmacokinetics,and Immunogenicty of Plonmarlimab in Subjects With Acute Gouty ArthritPhase IIRECRUITING
NCT06984588A Study to Compare Uliledlimab Combined With Toripalimab, Toripalimab Monotherapy, and Pembrolizumab Monotherapy in Patients With PreviouslyPhase II/IIIACTIVE NOT RECRUITING
NCT07005336A Study to Compare Uliledlimab Combined With Sintilimab and Chemotherapy Versus Sintilimab Combined With Chemotherapy in Patients With PreviPhase IIACTIVE NOT RECRUITING
NCT04633057A Study to Evaluating the Efficacy and Safety of Recombinant Long-acting Human Growth Hormone (TJ101) in Children With Growth Hormone DeficiPhase IIICOMPLETED

Explore interactive annual charts and M&A subsidiary rollups in the TJ Biopharma Co Interactive Dossier, benchmark peers in Oncology and Hematology, or review the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI